AGA Medical expands Amplatzer line
This article was originally published in The Gray Sheet
Executive Summary
Firm launches Amplatzer Muscular VSD Occluder for closure of complex ventricular septal defects following PMA approval Sept. 7. The device, which is placed via a transcatheter procedure in patients at high risk for surgical closure, is the latest addition to AGA's Amplatzer line. Also available in the United States are the Amplatzer septal occluder for atrial septal defects, and the Amplatzer duct occluder for closure of patent ductus arteriosus defects. The firm also offers vascular plugs ("1The Gray Sheet" Sept. 3, 2007, p. 11)
You may also be interested in...
AGA Medical’s Pipeline Diversifies Into Vascular Space
AGA Medical, a maker of minimally invasive devices to treat heart defects, is expanding its product portfolio further into the vascular space
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.